Trastuzumab administration during pregnancy: an update

BACKGROUND: Over than one third (28–58%) of pregnancy-associated breast cancer (PABC) cases are characterized by positive epidermal growth factor receptor 2-positive (HER2) expression. Trastuzumab anti-HER2 monoclonal antibody is still the benchmark treatment of HER2-positive breast tumors. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Andrikopoulou, Angeliki, Apostolidou, Kleoniki, Chatzinikolaou, Spyridoula, Bletsa, Garyfalia, Zografos, Eleni, Dimopoulos, Meletios-Athanasios, Zagouri, Flora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074427/
https://www.ncbi.nlm.nih.gov/pubmed/33902516
http://dx.doi.org/10.1186/s12885-021-08162-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074427/
https://www.ncbi.nlm.nih.gov/pubmed/33902516
http://dx.doi.org/10.1186/s12885-021-08162-3

Ejemplares similares